Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-10
2007-04-10
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C424S001690
Reexamination Certificate
active
10514005
ABSTRACT:
Celiac Sprue and/or dermatitis herpetiformis are treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i) retain the to bind tightly to HLA molecules; (ii) retain the protcolytic stability of these peptides; but (iii) are unable to T cells.
REFERENCES:
patent: 6197356 (2001-03-01), Girsh
patent: 2004/0241664 (2004-12-01), Dekker et al.
patent: 0 905 518 (1999-03-01), None
patent: WO 94/26774 (1994-11-01), None
patent: WO 01/25793 (2001-04-01), None
Database Derwent, Acc-No. 1996-329479, JP-08151396A, HLA-binding oligopeptide and an immuno: regulator contg, it-used in the treatment of auto: immune diseases, Abstract, Jun. 11, 1996.
Khosla Chaitan
Kim Chu-Young
Quarsten Hanne
Sollid Ludvig M.
Audet Maury
Bozicevic Field & Francis LLP
Sherwood Pamela J.
The Board of Trustees of the Leland Stanford Junior University
Tsang Cecilia J.
LandOfFree
Drug therapy for celiac sprue does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug therapy for celiac sprue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug therapy for celiac sprue will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3796125